Spots Global Cancer Trial Database for gedatolisib
Every month we try and update this database with for gedatolisib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009 | NCT05134922 | Breast Neoplasm... | Gedatolisib | 18 Years - | Celcuity Inc | |
| Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | NCT03065062 | Lung Cancer Squ... Solid Tumors Head & Neck Can... Pancreatic Canc... | Palbociclib Gedatolisib | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) | NCT02920450 | Non-Small Cell ... | Gedatolisib Paclitaxel Carboplatin | 18 Years - 90 Years | University of Florida | |
| Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009 | NCT05134922 | Breast Neoplasm... | Gedatolisib | 18 Years - | Celcuity Inc | |
| An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer | NCT03243331 | Triple Negative... Metastatic Brea... | Gedatolisib PTK7-ADC | 18 Years - | Indiana University | |
| Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) | NCT02920450 | Non-Small Cell ... | Gedatolisib Paclitaxel Carboplatin | 18 Years - 90 Years | University of Florida | |
| Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer | NCT03698383 | HER2-positive B... Metastatic Brea... | Trastuzumab bio... | 19 Years - | Korean Cancer Study Group | |
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | NCT06190899 | mCRPC (Metastat... Genital Disease... Urogenital Dise... Prostatic Disea... Prostatic Neopl... Prostate Cancer | Gedatolisib Darolutamide | 18 Years - | Celcuity Inc | |
| Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | NCT03065062 | Lung Cancer Squ... Solid Tumors Head & Neck Can... Pancreatic Canc... | Palbociclib Gedatolisib | 18 Years - | Dana-Farber Cancer Institute | |
| Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") | NCT03400254 | Breast Cancer | Hydroxychloroqu... Gedatolisib | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers | NCT03911973 | TNBC - Triple-N... | Gedatolisib Talazoparib | 18 Years - | Big Ten Cancer Research Consortium |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
